New Low-Risk TAVR Clinical Trial Results! [Video]

Once again, we’re hearing more promising news about low risk transcatheter aortic valve replacement (TAVR) clinical trial.

Medtronic, a healthcare technology company and global leader in heart valve manufacturing, recently announced its 4-year outcomes from the Medtronic Evolut Low Risk TAVR Clinical Trial, and the research continues to yield encouraging results.

So you know, the U.S. Food and Drug Administration (FDA) first approved TAVR procedures in 2011 for patients at extreme risk who are not candidates for surgical aortic valve replacement (SAVR) with severe aortic stenosis. In 2016, intermediate surgical risk patients were approved for the TAVR procedure. The Medtronic Evolut Low Risk TAVR Clinical Trial, which evaluates TAVR against SAVR for low surgical risk patients, helped extend the FDA’s TAVR approval for low-risk patients in 2019. However, even with the FDA approval, Medtronic continues to follow …